Alexion Announces Interim Results From Phase 2 Trials Of Eculizumab (Soliris(R)) In Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Links shared publicly online about this topic.
- 783total visits
Alexion Announces Interim Results From Phase 2 Trials Of Eculizumab (Soliris(R)) In Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced that its two open-label Phase 2 studies investigating eculizumab (Soliris®) as a treatment for patients with atypical Hemolytic Uremic Sy
View full resource at medicalnewstoday.com
Tags: Kidney Failure, Disease and Condition, Pharma, Phase 2 Clinical Trial
Most Recently Shared on October 22, 2010 at 2:06 pm By:
Alexion Announces Interim Results From Phase 2 Trials Of Eculizumab (Soliris(R)) In Patients With Atypical Hemolytic U... http://mnt.to/3Lzr
Alexion Announces Interim Results from Phase 2 Trials of Eculizumab (Soliris) in Patients with atypical Hemolytic Uremic Syndrome (aHUS) - Drugs.com MedNews
drugs.com — “Data Accepted for Presentation at American Society of Nephrology Annual Meeting in November Oct 20, 2010 - Alexion Pharmaceuticals, Inc. (Nasdaq ALXN) today ann” View full resource at drugs.com
Most Recently Shared on October 21, 2010 at 8:16 pm By:
Drugs and Devices OW OW Health
Alexion Announces Interim Results from Phase 2 Trials of Eculizumab (Soliris) in Patients with atypical Hemol... http://bit.ly/cS4bgM #drug
Advertisement
